VERA
$39.32
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion pr...
Recent News
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment
Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders.
This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock
Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide.
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision
Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.
Does FDA Priority Review And Phase 3 Win For Atacicept Redefine The Bull Case For Vera (VERA)?
Vera Therapeutics reported that for the full year ended December 31, 2025, its net loss widened to US$299.62 million from US$152.15 million, while also announcing positive Phase 3 data for atacicept in IgA nephropathy and receiving FDA priority review with a July 7, 2026 PDUFA date. These advances move atacicept closer to potential approval and commercialization, supported by 2025 equity and debt financings that management says strengthen the balance sheet beyond an initial U.S. launch...
Analysts Bullish on Vera Therapeutics (VERA) Amid New Commercial Chief Appointment
Vera Therapeutics Inc. (NASDAQ:VERA) is one of the 13 hot stocks to buy with the highest upside potential. As of February 13, nearly 90% of analysts who cover the stock have assigned a Buy or equivalent rating. The consensus 1-year median price target of $73 implies a 76% upside. Earlier, on January 28, Vera Therapeutics […]